Skip to content. | Skip to navigation

Personal tools
Log in


You are here: Home / Faculty / Dr. Marianne Sadar, PhD / Publications / Marianne Sadar Publications

Marianne Sadar Publications

Complete Publications List updated March 2019

Book Chapters

  1. Myung JK and Sadar MD. Proteomics and Prostate Cancer in Genomics and Proteomics. Concepts, Technologies and Applications. Eds, Thangadurai D and Sangeetha J. Bioscience Publications. 2015. pp 143-187
  2. Tien AH and Sadar MD. Androgen-Responsive Gene Expression in Prostate Cancer Progression in Androgen-Responsive Genes in Prostate Cancer. Ed, Wang Z. Springer Publishers. 2013. pp 135-153.
  3. Sadar MD. Role of cAMP in regulating the androgen receptor in Androgen Action in Prostate Cancer. Eds, Tindall DJ and Mohler JL. Springer Publishers. 2009. pp 465-503.

Peer-Reviewed Publications:

  1. Shimizu Y, Tamada S, Kato M, Hirayama Y, Takeyama Y, Iguchi T, Sadar MD, Nakatani T. Androgen receptor splice variant 7 drives the growth of castration-resistant prostate cancer without being involved in the efficacy of taxane chemotherapy. J Clin Med. 2018 Nov 16;7(11).
  2. Hirayama Y, Sadar MD. Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer? AME Med J 2018;3:66.
  3. Ito Y and Sadar MD. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology. 2018 Feb 16;10:23-32. 
  4. Tien AH and Sadar MD. Order within a disordered structure. Structure. 2018 Jan 2;26(1):4-6.
  5. Leung JK and Sadar MD. Non-genomic actions of the androgen receptor in prostate cancer. Frontiers In Endocrinology. 2017 Jan 17;8:2.
  6. Myung JK, Wang G, Chiu HH, Wang J, Mawji NR, Sadar MD. Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. PLoS One. 2017 Mar 17; 12(3):e0174134. doi: 10.1371/journal.pone.0174134. eCollection 2017. PMID: 28306720
  7. Leung JK and Sadar MD. Non-genomic actions of the androgen receptor in prostate cancer. Frontiers In Endocrinology. Published on-line January 4, 2017. 
  8. Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L, Wen JG, Andersen RJ, Sadar MD. Sintokamide A is a Novel Antagonist of Androgen Receptor that Uniquely Binds Activation Function-1 in its Amino-Terminal Domain. J Biol Chem. 2016 Oct 14;291(42):22231-22243. PMID: 27576691
  9. Imamura Y, Tien AH, Pan J, Leung JK, Banuelos CA, Jian K, Wang J, Mawji NR, Fernandez JG, Lin KS, Andersen RJ and Sadar MD. An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. J. Clin. Invest. Insight. 2016;1(11):e87850. doi:10.1172/jci.insight.87850. PMID: 27525313
  10. Obst JK and Sadar MD. Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation. Translational Cancer Research. doi: 10.21037/tcr.2016.07.35.
  11. Antonarakis ES, Chandhasin C, Osbourne E, Luo J, Sadar MD, Perabo F. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. The Oncologist, 2016 Sep 14. pii: theoncologist.2016-0161. [Epub ahead of print]. PMID: 27628492
  12. Imamura I, Sadar MD. Androgen Receptor targeted therapies in Castration-Resistant Prostate Cancer; bench to clinic. International J. Urol. 2016 Aug;23(8):654-65. doi: 10.1111/iju.13137. PMID: 27302572
  13. Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD. Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res. 2016 Sep 1;22(17):4466-77. PMID: 27140928
  14. Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD. Co-targeting Androgen Receptor Splice Variants and mTOR signaling pathway for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Dec 28. pii: clincanres.2119.2015.
  15. Martin S, BanuelosCA, Sadar MD, Kyprianou N. N-Terminal Targeting of Androgen Receptor Variant Enhances Response of Castration Resistant Prostate Cancer to Taxane Chemotherapy. Molecular Oncology. 2015 March 31; 9(3):628-639.  2014 Nov 15. pii: S1574-7891(14)00263-4. doi: 10.1016/j.molonc.2014.10.014.
  16. BanuelosCA, Lal, A, Tien AH, Shah N, Yang YC, Mawji NR, Meimetis LG, Park J, Kunzhong J, Andersen RJ, Sadar MD. Characterization of niphatenones that inhibit androgen receptor N-terminal domain. Plos One 2014 Sep 30;9(9):e107991
  17. Myung JK, BanuelosCA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 2013 Jul 1;123(7):2948-60. [Epub ahead of print]. Faculty of 1000. 718015980?bd=1&ui=5049.
  18. Yang YC, Meimetis L, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD. Spongian diterpenoids inhibit androgen receptor activity. Mol Cancer Ther. 2013 May;12(5):621-31.
  19. Myung JK and Sadar MD. Large scale phosphoproteome analysis of LNCaP human prostate cancer cells. Molecular Biosystems. 2012 Aug;8(8):2174-82.DOI:10.1039/c2mb25151e.
  20. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ. Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity. J Med Chem. 2012 Jan 12;55(1):503-14. Faculty of 1000, FFA rating: 6.
  21. Haile S, Lal A, Myung J-K. Sadar MD. FUS/TLS is a co-activator of the androgen receptor in prostate cancer cells. Plos One. 2011;6(9):e24197. 2011 Sep 1.
  22. Sadar MD. Advances in Small Molecule Inhibitors of Androgen Receptor for the Treatment of Advanced Prostate Cancer. World J Urol. 2012 Jun;30(3):311-8. doi: 10.1007/s00345-011-0745-5.
  23. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011 Dec;68(24):3971-81 2011 Jul 12.
  24. Quayle SN, Sadar MD. 14-3-3 sigma increases the transcriptional activity of the androgen receptor in absence of androgens. Cancer Lett. 2007, Aug 28;254(1):137-45.
  25. Quayle SN, Hare HA, Delaney AD, Hirst M, Hwang D, Schein JE, Jones SJM, Marra MA, Sadar MD. Novel expressed sequences identified in a model of androgen independent prostate cancer. BMC Genomics,2007, 8,1:32.
  26. Sadar MD. Small Molecule Inhibitors Targeting the “Achilles’Heel” of Androgen Receptor Activity. Cancer Research. 2011 Feb 15;71(4):1208-13.
  27. Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Medical Genomics, 2010 Sep 24;3:43.
  28. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos AC, Williams DE, McEwan IJ, Wang YZ, Sadar MD. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010 Jun 15;17(6)535-46. Faculty of 1000, FFA rating: 9.
  29. Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout GW, Squire JA, Wang YZ. Development of metastatic and non-metastatic tumor lines from a patient’s prostate cancer specimen-Identification of a small subpopulation with metastatic potential in the primary tumor. The Prostate 2010 Nov 1;70(15):1636-44.
  30. Chiu HHL, Yong TMK, Wang J,Wang Y,Vessella RL, Ueda T, Wang YZ, Sadar MD. Induction of Neuronal Apoptosis Inhibitory Protein Expression in Response to Androgen Deprivation in Prostate Cancer. Cancer Letters, 2010 Jun 28;292(2):176-85.
  31. Romanuik TL, Wang G, Holt RA, Marra MA, Sadar MD. Identification of novel androgen-responsive genes by deep sequencing of LongSAGE libraries. BMC Genomics, 2009, Oct 15;10:476.
  32. Romanuik TL, Ueda T, Le N, Haile S, Yong TMK, Thomson T, Vessella RL, Sadar MD. Novel biomarkers for prostate cancer including non-coding transcripts. Am J Pathol. 2009 Dec;175(6):2264-76.
  33. Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TMK, Jelescu-Bodos AE, Blaszczyk N., Vessella RL, Masri B, and Sadar MD. Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Research, 2009 Apr 15;69(8):3433-42.
  34. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009 Jun 10;27(17):2787-92. Faculty of 1000, FFA rating: 8.
  35. Wang G, Wang J, and Sadar MD. Crosstalk between the androgen receptor and β-catenin pathways in castrate-resistant prostate cancer. Cancer Research, 2008 Dec 1;68(23):9918-27.
  36. Sadar MD, Williams DE, Mawji NR, Patrick BO, Chasanah E, Irianto HE, Van Soest R, Andersen RJ. (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Letts., 2008 Nov 6;10(21):4947-50.
  37. Lin D, Watahiki A, Zhang F, Liu L,Ling V, Sadar MD, English J, Fazli L, Gleave M,  So A, Gout PW Wang Y-Z. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis. Cancer Research.2008 Jun 1;68(11):4352-9.
  38. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancerProc. Natl. Acad. Sci. USA. 2007 Jan 16: 104(4)1331-1336. Faculty of 1000, FFA rating 6. 
  39. Wang G, Jones SJM, Marra MA, Sadar MD. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene. 2006 Nov 23; 25(55), 7311-7323.
  40. Bainbridge MN, WarrenRL, Hirst M, Romanuik TL, Zeng T, Go A, DelaneyAD, GriffithM, HickenbothamM, Magrini V, MardisER, Sadar MD, Siddiqui AS, Marra MA, Jones SJM. Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006 Sep 29;7:246.
  41. Comuzzi B, Sadar MD. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience Reviews 2006 July 3(1):61-81.
  42. Wang G, Sadar MD. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem. 2006 May 1;98(1):36-53.
  43. Quayle SN, Sadar MD. A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics. 2006 May;87(5):633-7.
  44. Sobel RE, Wang Y, Sadar MD. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In Vitro Cell Dev Biol Anim. 2006 Jan-Feb;42(1):33-9.
  45. Ueda T, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T. Interleukin-4 in patients with prostate cancer. Anticancer Res.2005 Nov-Dec;25(6C):4595-8.
  46. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005 Nov;85(11):1392-404.
  47. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Coetz L, Xue H, Sadar MD, Shappell SB, Cunha GR, Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. The Prostate. 2005 Jul 1;64(2):149-59.
  48. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem. 2005 Apr;51(4):695-707. Epub 2005 Feb 3.
  49. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. J Urol. 2005 Feb;173(2):360-72.
  50. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. J Urol. 2005 Feb;173(2):342-59.
  51. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar MD, Gleave ME, Vielkind J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004 Sep 1;64(17):5929-33.
  52. Meehan KL, Sadar MD. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics. 2004 Apr;4(4):1116-34.
  53. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res. 2004 Mar 1;10(5):1860-9.
  54. Meehan KL, Sadar MD. Androgens and androgen receptor in prostate and ovarian malignancies. Front Biosci. 2003 May 1;8:d780-800.
  55. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem. 2002 Oct 11;277(41):38087-94.
  56. Sadar MD, Akopian VA, Beraldi E. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther. 2002 Jun;1(8):629-37.
  57. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002 Mar 1;277(9):7076-85.
  58. Sadar MD, Andersson TB. Regulation of cytochrome P450 in a primary culture of rainbow trout hepatocytes. In Vitro Cell Dev Biol Anim  2001 Mar; 37(3): 180-4.
  59. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res.2000 Oct 15; 60(20): 5825-31.
  60. Bruchovsky N, Klotz LH, Sadar MD, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol.  2000 Fall;4(3):191-9;discussion 201.
  61. Sadar MD, Hussain M, Bruchovsky N. Prostate Cancer: Molecular Biology of Early Progression to Androgen Independence. Endocr Relat Cancer.1999 Dec; 6(4): 487-502. Most cited prostate publication in this journal and 8th overall. 
  62. Sadar MD. Androgen-independent induction of PSA gene expression via cross-talk between the androgen receptor and PKA signal transduction pathways. J Biol Chem. 1999 Mar 19;274(12): 7777-83. 
  63. Gleave ME, Sato N, Sadar MD, Yago V, Bruchovsky N, Sullivan L. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP Tumor Model. J Cell Biochem. 1998 Jun 1;69(3):271-81.
  64. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 1997 Jul 11;272(28): 17485-94. 
  65. Sadar MD, Westlind A, Blomstrand F, Andersson TB. Induction of CYP1A1 by GABA receptor ligands.  Biochem Biophys Res Commun.1996 Dec 4;229(1):231-7.
  66. Bruchovsky N, Sadar MD, Akukura K, Goldenberg SL, Matsuoka K, Rennie PS. Characterization of 5-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol. 1996 Dec; 59(5-6):397-404.
  67. Sadar MD, Blomstrand F, Andersson TB. Phenobarbital induction of cytochrome P4501A1 is regulated by cAMP-dependent protein kinase-mediated signaling pathways in rainbow trout hepatocytes. Biochem Biophys Res Commun. 1996 Aug 14;225(2):455-61.
  68. Sadar MD, Ash R, Sundqvist J, Olsson PE, Andersson TB. Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes. J Biol Chem. 1996 Jul 26;271(30):17635-43.
  69. Sadar MD, Ash R, Andersson TB. Picrotoxin is a CYP1A1 inducer in rainbow trout hepatocytes. Biochem. Biophys. Res. Commun. 1995 Sep 25;214(3):1060-6.
  70. Rogers IH, MacDonald JS, Sadar MD.  Uptake of selected organochlorine contaminants in fishes resident in the Fraser River estuary, Vancouver, British Columbia. (1992)  Water Poll. Res. J. Canada, 27, 733-749.
  71. McLean E, Sadar MD, Devlin RH, Souza LM, Donaldson EM. Growth promotion in coho salmon (Oncorhynchus kisutch) following parenteral administration of recombinant porcine somatotropin: comparison between two ploidy states. (1991)  Aquat. Living Resource.  4, 155-160.

Conference Proceedings:

  1. Sadar, MD. Androgen Receptor: Recent Advances in Targeting the Androgen Receptor for Prostate Cancer Prevention and Therapy. (2012). AACR Annual Meeting Education Series.
  2. Sadar, MD. Androgen receptor: New Points of Attack. (2012) GU ASCO.
  3. Bruchovsky N, Goldenberg SL, Mawji NR, Sadar MD. Evolving aspects of intermittent androgen blockage for prostate cancer: diagnosis and treatment of early tumor progression and maintenance of remission.  (2001) In, Andrology in the 21st Century, Proceedings of the VIIth International Congress of Andrology, Robaire, B., Chemes, H., and Morales, C.R. (eds), pp. 609-623. Medimond Inc. Citations: 5
Page last modified Mar 21, 2019